leadf
logo-loader
viewWillow Biosciences Inc.

Willow Biosciences says it will be the first company to launch biosynthetically-produced THC in Canada

The Canadian company plans to commercialize the proprietary THC-producing yeast strain after it successfully launches its CBG-producing strain early this year

Willow Biosciences Inc. -
Willow’s in-house process creates a consistent, scalable and sustainable high-purity product that can be used in a multitude of different industries

Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) has said it is planning to become the first company to launch biosynthetically-produced THC in Canada.

Willow’s in-house process creates a consistent, scalable and sustainable high-purity product that can be used in a multitude of different industries, from consumer packaged goods to pharmaceuticals.

The Canadian company announced Tuesday that it plans to commercialize the proprietary THC-producing yeast strain after it successfully launches its CBG-producing strain early this year. In December, Willow told shareholders it expects its first sales of CBG in the second quarter of 2021 -  six months ahead of expectations.

READ: Willow Biosciences moves towards revenue generation as it expects first sales of CBG in second quarter of 2021

The successful production of THC demonstrates the versatility of Willow’s platform, CEO Trevor Peters told Proactive. Willow is planning to scale up the process to get the THC strain to a point where it is commercially ready by the end of 2021, and potentially even start manufacturing.

“We’re making a product that has a very big addressable market in Canada,” Peters said. “Being able to produce THC at a high level of purity is not something that’s available today. There’s no plant-based contaminants that would come through the extraction process and could potentially spoil a beverage or food item or something similar.”

Willow told investors that, through conversations with prospective customers in Canada, it believes there is a high demand for consistent, high-purity THC. “The flavourless, odorless attributes of our finished product make it suitable as a core ingredient for the cannabis 2.0 market in Canada,” Peters said. “There is also strong demand for a more sustainable and environmentally friendly way to produce THC.”

More compounds in the pipeline

With two cannabinoids now successfully produced, Willow can now turn its attention to biosynthesizing additional compounds such as THCV (tetrahydrocannabivarin) that research suggests works as an appetite suppressant and could help with diabetes, among other effects. There’s also CBN (cannabinol), another cannabinoid compound that could be a potent antibacterial agent.

“Once we’ve done something once, we can more quickly move to something else within our overall portfolio,” Peters told Proactive. “Both THCV and CBG will be accelerated through the work we are doing on TCH and CBG.”

Peters told investors that Willow’s manufacturing process is 50 to 500 times more efficient than indoor cultivation and is the “next evolution of sustainable cannabinoid manufacturing.”

The firm said it is planning to target the adult-use market in Canada first, but is keeping a close eye on the regulatory environment in the US in case legalization should occur with the incoming presidential administration.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Willow Biosciences Inc.

Price: 1.36 CAD

TSX:WLLW
Market: TSX
Market Cap: $157.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Willow Biosciences Inc. named herein, including the promotion by the Company of Willow Biosciences Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Willow Biosciences plans to use proprietary yeast strain to produce THC for...

Willow Biosciences (TSE: WLLO- OTCQX: CANSF) CEO Trevor Peters joined Steve Darling from Proactive with news the company has announced plans to commercially launch their proprietary yeast strain for the production of THC for Cannabis 2.0. Peters talks about the research that has gone into...

on 19/1/21

3 min read